**TABLE G28. CHALLENGES SCORES –SLIT– PEDIATRICS**

| **Study** | **Allergen** | **Arms** | **Time of measure** | **Scale description** | **SCORE** | **Value Pre** | **Value post** | **Comparative values** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Hirsch,  199729 | Dust mite | SLIT  Placebo | 1 year | nasal provocation (acoustic rhinometry) | SBU/ml 40% reduction nasal flow | 1240  470 | 1380  1790 | SLIT pre vs post p NS  Placebo pre vs post p<0.01  SLIT vs Placebo p<0.05 |
| Hirsch,  199729 | Dust mite | SLIT  Placebo | 1 year | Bronchial histamine provocation test, PC20 FEV1 (mg/mL) | Concentration inducing 20% reduction of FEV1 | 0.7  1.7 | 0.52  1.5 | SLIT vs Placebo p NS |
| la Rosa, 199923  Leonardi 200924 | Parietaria | SLIT  Placebo | 2 years | ocular conjunctival provocation test | 0-3 | 23 IR/mL18 IR/mL | 35  15 | SLIT vs Placebo p =0.02 |
| Lue  200619 | Dust mite | SLIT  Placebo | 6 months | FEV1 |  | 75  80 | 90  82 | SLIT pre vs post p = 0.001  Placebo pre vs post p =0.48  SLIT vs Placebo p =0.93 |
| Niu  200620 | Dust mite | SLIT  Placebo | 24 weeks | FEV1 |  | 85  90 | 95  90 | SLIT pre vs post p=0.048  Placebo pre vs post p=0.977  SLIT vs Placebo NS |
| Ippoliti, 200338 | Dust mite | SLIT  Placebo | 6 months | FEV1 |  | 83.4  80.7 | 92.6  81.2 | SLIT pre vs post p < 0.001  Placebo pre vs post p NS  SLIT vs Placebo NR |
| Lue  200619 | Dust mite | SLIT  Placebo | 6 months | Morning PEFR |  | 185  210 | 197  225 | SLIT pre vs post p=0.244  Placebo pre vs post p=0.086  SLIT vs Placebo p=0.132 |
| Lue  200619 | Dust mite | SLIT  Placebo | 6 months | Evening PEFR |  | 190  225 | 215  235 | SLIT pre vs post p=0.008  Placebo pre vs post p=0.253  SLIT vs Placebo p=0.341 |
| Niu  200620 | Dust mite | SLIT  Placebo | 24 weeks | PEF |  | 65  70 | 75  77 | SLIT pre vs post p=0.001  Placebo pre vs post p=0.075  SLIT vs Placebo NS  Pre/post SLIT: FVC p=0.042, FEV1 p=0.048 |
| Stelmach  201127 | Grass mix | SLIT pre-coseasonal SLIT continuous  placebo | 2 years (2010) | FEV1  (% predicted) |  | 98.3(2.8 SEM)  101.9(2.4)  99.7(2.4) | 100.2(2.9)  102.8(2.7)  102.3(1.9) | No significant changes within and among all groups throughout study. |
| Stelmach  201127 | Grass mix | SLIT pre-coseasonal SLIT continuous  placebo | 2 years | Morning PEF  (% predicted) | Compare season 2009 to season 2010 | NR | 99.5 (3.1)  98 (3.9)  90.1 (4.9) | No significant changes within and among all groups throughout study. |
| Stelmach  201127 | Grass mix | SLIT pre-coseasonal SLIT continuous  placebo | 2 years | PD20 (mg) |  | NR | 0.25 (0.02)  0.19 (0.03)  0.25 (0.02) | No significant changes within and among all groups throughout study. |
| Marogna  200828 | Birch and Grass | SLIT  Pharma-cotherapy | 3 years | Methacholine challenge | # of patients with positive Mch test | 82 (56.9%)  47 (65.3%) | 23 (17.7%)  31 (47.7%) | SLIT pre/post, p<0.001,  Controls pre/post, NS p=0.5  Post: SLIT vs control, p<0.001,  OR=0.24 (0.12-0.47) |
| Pajno 200332  Pajno 200433 | Parietaria | SLIT  Placebo | 2 years | Methacholine challenge, PC20 (mg/mL) | Compared PC20 in Spring 1999 and Spring 2001 | 3.37 +/- 2.99  2.44 +/- 2.25 | 9.10 +/- 7.7  2.46 +/- 2.26 | SLIT pre vs post, p=0.01,  Placebo pre vs post, p NS  Pre: SLIT vs placebo, NS  Post: SLIT vs placebo, p=0.001 |
| Pajno 200332  Pajno 200433 | Parietaria | SLIT  Placebo | 2 years | FEV1  (% predicted) | Spring 1999 compared to Spring 2001 | 82.0 (5.4)  78.9 (5.9) | 88.4 (3.7)  75.6 (4.9) | SLIT showed trend toward improvement during pollen seasons, although not significant |
| Bahceciler 200130 | Dust Mite | SLIT  Placebo | 6 months | Peak Expiratory Flow (%) |  | 97 (77-117)  99 (82-128) | 99 (75-116)  76 (62-106) | SLIT vs placebo PEF Significant improvement p=0.04  SLIT pre vs post, NS  Placebo pre vs post, p=0.028 |
| Bahceciler200130 | Dust Mite | SLIT  Placebo | 6 months | FEV1 (%) |  | 95 (75-113)  101 (75-115) | 100 (78-119)  93 (61-104) | No significant improvement vs placebo |
| Bahceciler200130 | Dust Mite | SLIT  Placebo | 6 months | PC20 (mg/ml) |  | 0.28 (0.03-3.8)  0.78 (0.04-1.8) | 0.85  (0.17-2.2)  0.98  (0.18-3.9) | No significant improvement vs placebo |
| Tari,  199031 | Dust mite | SLIT  Placebo | 18 months | Nasal provocation test (NPT) |  | NR | 5.2x increase  No increase | SLIT vs Placebo p< 0.01  Provocation dose significantly increased compared with initial values in SLIT (5.2 x increase), which was not observed in placebo |
| Tari,  199031 | Dust mite | SLIT  Placebo | 12 months | Bronchial provocation challenge | FEV-1 Mch challenge (µg)  (aspecific) | SLIT group  280.8 +/- 16.4 | SLIT group  502 +/- 26.6 | SLIT pre vs post, p< 0.05  Threshold value increased 1.78x |
| Tari,  199031 | Dust mite | SLIT  Placebo | 12 months | Bronchial provocation challenge | FEV1 Dust mite challenge (specific) | SLIT  170.8 +/-18.4 | SLIT  300.3 +/- 28.4 | SLIT pre vs post p< 0.05  Threshold value increased 1.76x |
| Valovirta, 200636  Savolainen 200637 | Tree mix | SLIT high dose  SLITlow dose  Placebo | Peak season | Conjunctival provocation test | Positive test if 2/4 sx present (itch, red, tears, swelling) | NR | NR | No statistically significant differences between treatment groups |
| Valovirta, 200636  Savolainen 200637 | Tree mix | SLIT high dose  SLITlow dose  Placebo | Peak season | Methacholine bronchial provocation test (MBPT) | PD20, continued until fall in FEV1 of >20% | NR | NR | No statistically significant differences between treatment groups |